Removal, by selective reduction, of the acetylglucosamine from teicoplanin A2-2 (CTA/2) produced the 34-de(acetylglucosaminyl)-34-deoxy pseudoaglycone (II). This compoundwas more active in vitro than CTA/2against coagulase-negative staphylococci (CNS).
The influence of the sugars on the in vitro and in vivo activity of teicoplanin has been matter of investigation for years in order to establish structure-activity relationships among derivatives of teicoplanin, its pseudoaglycones and aglycone.1* In particular teicoplanin derivatives were studied for their activities against coagulase-negative staphylococci (CNS), and Gram-negative bacteria (which are generally resistant to glycopeptide antibiotics of the dalbaheptide group).2) A current challenge for glycopeptides is the emerging resistance in enterococci,3) which are often resistant to other first-line antibiotics.
By selective removal of the three sugars of teicoplanin A2 complex (CTA), or of component A2-2 (CTA/2, Fig. la ), four of the six possible pseudoaglycones and the aglycone were obtained (Fig. lb) . In particular, the stepwise acidic hydrolysis of teicoplanin gave the 56-de(acylglucosaminyl) (TB) and 34-acetylglucosaminyl (TC) pseudoaglycones, and the aglycone (TD). Demannosylation of CTA, to give the 42-demannosyl pseudoaglycone (DMCTA), and mannosylation of TD, to give the 42-mannosyl pseudoaglycone (MTD), were achieved by biotransformation methods.40 The differences in the antibacterial in vitro and in vivo properties between teicoplanin derivatives and their available sugar-deficient pseudo-aglycones and aglycone suggested it was possible to improve the anti-CNS activity with the synthesis of CTA-amidesand to pursue the anti-Gram-negative activity with the synthesis of TDamides.5'6) However, no such indication emerged from the activity of the above compounds against highly glycopeptide-resistant enterococci. To complete this investigation, only the de(acetylglucosaminyl) pseudoaglycones (GMTDand GTD) were missing. All attempts to selectively remove the acetylglucosamine from CTAwere unsuccessful due to the resistance of this sugar to enzymatic hydrolysis and its higher acidic stability than that of the other two sugars. A result was achieved under basic conditions, but through a^-elimination mechanism which produced unsaturated de(acetylglucosaminyl)-didehydrodeoxy pseudoaglycone I (Fig. 2a) . 7) Its antibacterial spectrum of activity was comparable to that of teicoplanin. In this paper the synthesis and activity of the saturated de(acetylglucosaminyl)-deoxy pseudoaglycone II (Fig. 2b) , its secondary amide derivatives III~VII (Fig. 3a) and dimethylamide VIII (Fig. 3b) are described.
Chemistry
Synthesis of deoxy-pseudoaglycone II The 34-de(acetylglucosaminyl)-34-deoxy pseudoaglycone II was prepared from CTA/2 by two different synthetic pathways (Methods a and b, Scheme 1). Method a is based on the catalytic hydrogenation (5% Pd/C, 1 atmosphere, room temperature) of the 35,52-ON bond of unsaturated pseudoaglycone I, which was obtained according to a procedure C80H84N8O27Cl2 C82H89N9O26C12
(treatment of CTA/2 with methanolic KOHin a DMF-DMSO3 : 2 solution) previously reported.7) HPLCwas unsuitable for following the reduction of compound I to compound II since I and II have the same retention time. Therefore, the progress of the reaction was monitored by *H NMRanalysis (decrease of signals, d, at S 4.13 and 4.76ppm, due to the 34-CH2 ofI, and related increase of signals, dd, at 3.00 and 3.25 ppm of the 34-CH2 protons ofII).
The discovery of a selective reaction for unsaturated compoundI provided a suitable method for the isolation and purification of II (Chart 1). Reduction of the C=Nbond of I with Zn at room temperature in concentrated HC1produced a more lipophilic molecular isomer IF (MW1660)a of II whose structure was not further investigated. As Chart 1. Chemical separation of derivative II from unsaturated compoundI.
a. Zn/HCI b. H2 (5% Pd/C) expected, II was resistant to these reduction conditions and was then purified by chromatographic resolution of the reaction mixture. The overall transformation yield of CTA/2into pure II by way of unsaturated compoundI was about 60%.
Method b. A more convenient, although less efficient (yield < 30%, Table 1 ) one-step procedure to obtain II involved direct reductive removal of the acetylglucosamine from CTA/2with sodium borohydride at room temperature in a DMF-MeOH (2: 1) solution. Also with this reaction a small amount of unsaturated compound I formed which was separated as described above.
Amidation of the 38-COOH (Scheme 2) Preliminary protection of the terminal amino group of II was necessary to avoid undesired intermolecular side reactions. Benzylcarbamate derivative N15-CBZ-II was obtained by treatment of II with benzyl chloroformate (CBZ-C1) in DMFat room temperature in the presence of triethylamine (TEA). The N1 5-CBZderivatives of amides III~VII were prepared by either direct reaction of the carboxyl group of N15-CBZ-II with the appropriate amineb, using diphenyl phosphorazidate (DPPA) as the condensing in DMSOin the presence of DPPAand TEA, followed by removal of the BOCprotective groups with dry TFA. hydrogenolytic conditions (5% Pd/C, 1 atmosphere, room temperature).
Amides of deoxy-pseudoaglycone II from CTA-amides (Scheme 3) Method b was also applied to the preparation of dimethyl amide VIII (Table 1 , Fig. 3b ) from the corresponding amide (T-VIII) of CTA/2and as an alternative synthesis of dimethylaminopropyl amide III from parent CTA/2-amide (T-III).
Structure Elucidation
The structure of compoundII was elucidated by XHNMRspectroscopy and FAB-MSspectrometry. CompoundII. From NMRdata ( Table 3 ) it appears that, in addition to the absence of the 34-acetylglucosamine and the presence of the 34-CH2, pseudoaglycone II differs from CTA/2 in the conformation of the 51,52-peptide bond which is cisoid in CTA/2 (52-NH, S 6.09ppm) and TD (52-NH,
while it is very likely in the transoid conformation in II (down field shift of the 52-NH proton to 3 7.90ppm).7) Reduction in II of the ON double bond present in I is confirmed by the FAB-MSspectrum of II (MW1660, 2 mass units higher than that of I). Amides of II. The XH NMRspectra of the secondary amides ofII show that the amidic moieties are present and that the conformation of the 51,52-peptide bond is cisoid (52-NH, S 6.80ppm) as in the teicoplanin amides. In contrast, the downfield shift of the 52-NH proton (S 7.85 ppm) in the spectrum of the intermediate cyanomethyl ester N1 5-CBZ-II-CMEindicates that the conformation of that linkage is probably transoid as in II. The same possible transoid conformation of the 51,52-peptide bond is shown by the tertiary amide VIII, as it results by comparing the XHNMRspectrum of VIII with that of the secondary amide III (Table 3 ).
Remarks.In "natural" teicoplanins, their ester and amide derivatives, as well as in the other glycopeptides of the dalbaheptide family, the 51,52-peptide linkage is always cisoid. The presence of the 34-benzylic hydroxyl group or sugars is hypothesized to stabilize the macrocyclic ring formed by amino acids, 5, 6 and 7 in the original conformation, by hindering any twisting in the left hand side of the molecule and thus preventing the 51,52-peptide bond from assuming the transoid orientation.
In deoxy pseudoaglycone II, the rearrangement of the 5,6,7-macrocyclic ring towards a thermodynamically more stable conformation, in which the 5 1 ,52-peptide bond is likely transoid, is permitted because of the absence of the above benzylic functions at position 34.
The conformational differences among the de(acetylglucosaminyl)-deoxy derivatives of teicoplanin might be explained by the formation of different hydrogen bonding systems (Chart 2) which would constrain the 5,6,7-macrocyclic ring in two different arrangements in which the 51,52-peptide bond is alternatively cisoid or transoid.
In deoxy pseudoaglycone II, its ester derivatives and tertiary amides, the transoid orientation of the 51,52-linkage might be stabilized by the only possible hydrogen bonding system involving the 37-NH proton and the 63-C=O oxygen in a five-membered ring.
In the secondary amides of II, there might be an alternative hydrogen bond between the amidic N-H proton and the carbonyl oxygen of adjacent 36,37-peptide linkage. The resulting seven-membered hydrogen bonding system might be favoured in this particular case by the proximity in the space of the amidic proton and the 36-carbonyl oxygen.c The consequent opposite orientation of the transoid 36,37-peptide bond in the two different hydrogen bonding systems is reflected in the different conformation of their 5,6,7-macrocyclic ring and 51,52-peptide linkage between the secondary amides and the other derivatives ofII.
Antibacterial
Activity The compounds were first tested against a panel of Gram-positive bacteria, including a CNSstrain of Staphylococcus haemolyticus for which the MIC of teicoplanin (CTA/2) is relatively high (8 jUg/ml).
As shown in Staphylococcus aureus and Enterococcus faecalis, dimethylamide VIII had almost the same spectrum of activity as compoundII.
Antibacterial Activity The compounds were first tested against a panel of Gram-positive bacteria, including a CNSstrain of Staphylococcus haemolyticus for which the MIC of teicoplanin (CTA/2) is relatively high (8 /zg/ml). As shown in Table 4 , deoxy pseudoaglycone II was more active than CTA/2against the S. haemolyticus strain and had similar activity against other Gram-positive bacteria. Though less active against Staphylococcus aureus and Enterococcus faecalis, dimethylamide VIII had almost the same spectrum of activity as compound II.
Secondary amides III~VI had activity similar to that of II against Streptococcus pyogenes and S. haemolyticus, but they were less active than either II or CTA/2against Staphylococcus aureus and Enterococcus faecalis. The most active compoundof this family was amide VII, which was very active against all of the isolates and was significantly more active than the other compounds, including DEC. 1994 CTA/2-amide T-VII, against S. pyogenes, S. haemolyticus, and Staphylococcus epidermidis. Preliminary tests with a highly glycopeptide-resistant enterococcus (L562, VanA) prompted investigation of the activity of amides III~VII against 7 isolates of VanAenterococci from various sources. As shown in Table 5 , amides III~VII had moderate activity against these isolates. CompoundVII was also tested against 15 isolates of S. pyogenes. As shown in Table 6 , compound VII was 4 to 16 times as active as CTA/2against these strains.
Conclusions
The reductive removal of the 34-acetylglucosamine from CTA/2 and its tertiary dimethylamide (T-VIII) produced 34-deoxy pseudoaglycone derivatives II and VIII, respectively, which were more active than teicoplanin against S. haemolyticus. In the structure of these compounds, the orientation of the 5 1 , 52-peptide bond appears changed from cisoid to transoid. This is probably due to the absence of a 34-hydroxyl group or sugar, one of which is always present in natural glycopeptides of the dalbaheptide group. It follows a different conformation of the 5,6,7-macrocyclic ring between teicoplanin and these 34-deoxy derivatives which does not allow a direct comparison of the two classes of compoundssuch as to establish VOL.47 NO. 12 THE JOURNAL OF ANTIBIOTICS 1503 the exact role of the acetylglucosamine in the activity of "natural" teicoplanin antibiotics. The effect of this sugar on the activity of teicoplanin amides can be deduced by comparing the activity of the secondary amides (III~VII) of deoxy pseudoaglycone II with that of the corresponding amides (T-III~T-VIII) of CTA/2, as these compounds all have the same overall conformation of the heptapeptide backbone. The most evident result is that the presence of the acetylglucosamine has a negative influence on the activity of teicoplanin amides against VanAenterococci.
Studies are in progress to assess whether the activity of the acetylglucosamine-missing secondary amides of II against these highly glycopeptide-resistant enterococci is due to increased affinity for the depsipeptide, a D-Alanyl-D-hydroxy acid (Fig. 4) 
Experimental
The progress of the reactions and the homogeneity of the final products were checked by HPLC. *H NMR spectra were recorded at 500 MHzon a Bruker AM500 NMR-spectrometer equipped with an Aspect 3000 computer. The spectra were obtained at 40°C in DMSO-d6 solution, using Me4Si (d 0.00 ppm) as internal reference.
FAB-MSpositive ion spectra were obtained on a Kratos MS-50 instrument fitted with a standard FABsource and a high-field magnet. The sample (~10nmol) was dispersed in few microliters of a-thioglycerol-diglycerol 1 : 1 matrix and bombarded with a 6~9 keV beam on Xe atoms.
The products were purified by reversed-phase column chromatography on silanized silica gel (0.063~0.2 mm; Merck). Reactions, column eluates, and final products were checked by HPLCperformed on a column Hibar (120 x 4.5 mm; Merck) prepacked with LiChrosorb RP-8 (10 /mi), using a Varian Model 5500 LC pump equipped with a 20-fA loop injector Rheodyne Model 7125 and a Varian Model 2050UV variable detector. Chromatogramswere recorded at 254nm. Elutions were carried out at a flow rate of 2ml/minute according to a linear step gradient from 20% to 60% of CH3CNin 0.2% aqueous HCO2NH4 in 30 minutes.
All derivatives were analyzed for N and Cl, on samples previously dried at 140°C under N2 atmosphere. Weight loss was determined by thermogravimetry (TG), at 140°C. Inorganic residue was determined after heating the samples at 900°C in O2 atmosphere. The analytical results obtained for N and Cl were within + 0.4% of the theoretical values. Solvent content (in general H2O, with traces of 1-BuOH) and inorganic residue were always less than 10%and 0.3%, respectively.
Most of the intermediate di-and polyamines are commercially available products which were purchased from Fluka-Chemie AGor Aldrich-Chemie Gmbh& Co. KG, with the exception of the branched tetramine N[(CH2)3NH2]3, used in the synthesis of amide VII, which was prepared according to a procedure previously described.6) The preparations of the intermediate unsaturated pseudoaglycone I7) and amides T-III~T-VIII5'6) of CTA/2 were also already reported.
Preparation of 34-De(acetylglucosaminyl)-34-deoxy
CTA/2 (II) Method a. A solution of 3.4 g (ca. 2mmol) of 34-de(acetylglucosaminyl)-35,52-didehydro-34-deoxy CTA/2 (I) in 300ml of a MeOH-0.04N HC1 (7 : 3) was hydrogenated (1 atm, room temperature) in the presence of 1.5 g of 5% Pd-C for 30 minutes, while absorbing 57ml of H2. After adding additional 2g of the same catalyst, hydrogenation was continued under the above conditions for 2 hours (further 70 ml of H2 was absorbed). The catalyst was filtered off and, after adding 600ml of a BuOH-H2O (2 : 1) mixture, the filtrate was concentrated at 25°C under reduced pressure to remove most of MeOH. The organic layer was separated and concentrated at 25°C under reduced pressure to a small (ca. 50 ml) volume. On adding ethyl acetate (350ml), the precipitated solid was collected, washed with Et2O and dried in vacuo at 40°C d The mechanism of resistance to glycopeptides in VanAenterococci is related to a modification in the structure of peptidoglycan precursors in which terminal D-Ala-D-Ala is substituted by a D-Ala-D-HBut residue. The peptide binding interaction in teicoplanin-like antibiotics is outlined in Fig. 4 . DEC. 1994 overnight, yielding 2.5 g of the title compound, as the hydrochloride.
Method b. To a stirred solution of 10g (ca. 5mmol) ofCTA/2 in 200ml of a DMF-MeOH (2: 1) mixture, 75 g (ca. 2mol) of NaBH4(pellets of ca. 0.4g each) was added at 0~5°C. The reaction mixture was stirred at room temperature for 24 hours and then it was poured into 1 liter of a MeOH-AcOH (85 : 15) mixture while cooling to 10~15°C. The resulting solution was concentrated at 45°C under reduced pressure to a volume of ca. 200ml and the precipitated solid was filtered off. Then, the filtered solution was concentrated at 50°C under reduced pressure to a small (ca. 20ml) volume. On adding Et2O (300ml), the precipitated solid (ca. 19g, containing inorganic salts and a 15 : 85 mixture6 of compounds I and II, respectively) was collected and re-dissolved in 500ml of a 10N HC1-DMF(1 :4) mixture at 0~5°C. Afterwards 25 g of Zn (powder) was added under vigorous stirring. The formation of a more lipophilic compound (II': HPLC, Rt 1 1.7 minutes) was observed within few minutes which derived from reaction by-product I. The transformation of I into II' was completed in 1 hour. Then, the insoluble matter was filtered off and 1.5 liter of H2Owas added to the filtered solution. The aqueous mixture was extracted with BuOH(1.5 liter) and the organic layer was washed with H2O several times (10 x 500ml) until the pH offinal aqueous layer was about 4. The butanolic phase was separated and concentrated at 45°C under reduced pressure to a small (ca. 50ml) volume. The resulting suspension was poured into 1 liter of a H2O-MeCN(8 : 2) mixture obtaining a solution which was loaded on a column of 1.5 kg of silanized silica gel in the same solvent mixture. The column was developed eluting with a linear gradient from 20 to 70% of MeCNin 0.001 n HC1in 20 hours at a flow rate of400ml/hour, while collecting 20ml-fractions. Those containing pure title compoundwere pooled and, after adding 2 volumes of BuOH,they were concentrated at 35°C under reduced pressure to a final volume of about 50 ml. On adding Et2O (200 ml), the precipitated solid was collected and dried in vacuo at room temperature overnight, yielding 2.37g of pure compound II, as the internal salt.
Preparation of Secondary Amides III~VI (Method d) General procedure. A solution of 4g (ca. 2.5mmol) of compound II and 0.36ml (ca. 2.6mmol) of TEAin 20ml of DMFwas stirred at room temperature for 30 minutes while adding 0.4ml (ca. 2.8 mmol) of benzyl chloroformate/ Then, 0.4ml (ca. 3.3 mmol) of TEA and 4ml (ca. 65 mmol) ofchloroaceto-nitrile were added and stirring was continued at room temperature for additional 20 hours. The reaction mixture was poured into 300 ml of ethyl acetate. The precipitated solid was collected and dried at room temperature in vacuo overnight, yielding 4.3 g of crude N15-CBZ-II-CME (HPLC, Rt 19.5 minutes). A 30mg-pure sample of this compound (from lOOmgof the crude product) was obtained by reversed-phase column chromatography under the same conditions described above in the purification of compoundII. To a stirred solution of4.2 g of crude N15-CBZ-II-CME in 30 ml ofDMF, 35 mmol of the appropriate amine was added and the resulting solution was stirred at room temperature overnight. Then, 25 ml of absolute ethanol was added, followed by 250ml of ethyl acetate. The precipitated solid was collected, washed with 100ml of Et2O, and then dried at room temperature in vacuo overnight, obtaining crude corresponding N1 5-CBZ-amide.
This product was dissolved in 350ml of a MeOH-0.01 n HC1 (7 : 3) mixture and the resulting solution was hydrogenated (1 atm, room temperature) in the presence of4 g of5% Pd-C for 2 hours, while absorbing 120~130ml of H2. The catalyst was filtered off and the filtrated solution was adjusted at pH 6.5 with 1 n NaOH.After adding 300ml of BuOHand 15g of silanized silica gel, solvents were evaporated at 40°C under reduced pressure. The solid residue was suspended in 200 ml of H2Oand the resulting suspension was loaded on a column of400 g of the same silanized silica gel in H2O. The column was developed eluting with a linear gradient from 10 to 80%ofMeCNin H2Oin 20 hours at a flow rate of 250ml/hour, while collecting 25 ml-fractions. Those containing pure title compounds were pooled and, after adding 2 volumes of BuOH,they were concentrated at 35°C under reduced pressure to a small volume (ca. 50 ml). The solid which separated was collected by centrifugation, washed with 10ml of H2O, then with 250ml of ethyl e The composition was determined by XHNMR spectroscopy. f Intermediate benzyl carbamate N15-CBZ-II was not isolated. Its formation, deduced from HPLCanalysis of the reaction mixture (disappearance of peak at Rt 8.1 minutes, corresponding to compound II, and formation of a new peak at Rt 13.2 minutes, corresponding to its benzyl carbamate) was then confirmed by the structure of cyanomethyl ester N15-CBZ-II-CMEwhich was isolated in a pure state after treatment of N15-CBZ-II with chloroacetonitrile.
acetate and 100ml of Et2O. After drying in vacuo at room temperature overnight, pure title compounds were obtained as the free bases.
Preparation of 3,3-Dimethylamino-l -propylamide HI From compound II (Method c).g To a stirred solution of8.3 g (5 mmol) of compound II and 1.4ml (ca. 10 mmol) of TEAin 100ml of DMF, 0.71 ml (ca. 5 mmol) of benzyl chloroformate was added at room temperature in 30 minutes.ll Then, 0.7 ml (ca. 5.5 mmol) of 3,3-dimethylamino-l-propylamine was added followed by 1.55g (ca. 5.5mmol) of diphenylphosphorazidate (DPPA), and stirring was continued at room temperature for 5 hours. On adding 500ml of Et2O, the precipitated solid (crude N15-CBZ-amide III) was collected and redissolved in 500ml of a MeOH-0.0l N HC1 (7 : 3) mixture. Hydrogenation to remove the CBZ-group and purification of crude amide III were then performed as described previously, yielding 4.1 g of pure title compound. From parent CTA/2-amide (T-III) (Method b). To a stirred solution of 20g (ca. 10mmol) of the 3,3-dimethylamino-l-propylamide of CTA/2 (T-III) in 3 liters of a DMF-MeOH(2 : 1) mixture, 200g (ca. 5.5mol) ofNaBH4is added in 90 minutes while cooling at 5~10°C. Stirring was continued at room temperature for 7 days and then the reaction mixture was poured into a solution of 320ml of glacial AcOHin 6 liters of MeOH, while cooling at 5~10°C. The resulting solution was concentrated at 35°C under reduced pressure until most methanol was evaporated. The solid which separated was filtered off and the filtered solution was concentrated at 50°C under reduced pressure to a final volume of about 300ml. On adding 1 liter of Et2O, the precipitated solid was collected and purified by reversed-phase column chromatography under usual conditions, yielding 6.5 g of the title compound. propyl]-l ,3-diaminopropane6) was added. The resulting solution was stirred at 10°C while adding dropwise, in 30 minutes, a solution of 2.5 ml (ca. lOmmol) of DPPA in 5 ml of DMSO. After stirring at room temperature overnight, the reaction mixture was poured into 500 ml of ethyl acetate. The precipitated solid was collected and re-dissolved in 100 ml of cold (0°C) TFA. After 30 minutes, 1 liter of ice-cold Et2O was added and the oil which separated was slurried with ethyl acetate (3 x 250ml), obtaining a solid which was collected and washed with 250ml of Et2O, yielding 21 g of crude N15-CBZ-amide VII. This product was not purified for the next hydrogenation step, which was run as described previously. Purification by reversed-phase column chromatography under usual conditions yielded 6.6g of the title compound.
Preparation of Dimethyl Amide VIII (Method b) To a stirred solution of 19.1 g (10mmol) ofCTA/2-dimethylamide T-VIII in 3 liter ofa DMF-MeOH (2: 1) mixture, 260g (ca. 7mol) of NaBH4was added portionwise in 2 hours while cooling at 5~10°C. Stirring was continued at room temperature for 5 days and then the reaction mixture was poured dropwise into a ice-cold solution of 500 ml of glacial AcOHin 6 liters of MeOH, while maintaining the temperature at 0~5°C. Most MeOHwas evaporated at 40°C under reduced pressure and the precipitated solid was filtered off. The filtered solution was concentrated at 55°C under reduced pressure to a final volume of about 500ml, then Et2O (1.5 liters) was added. The precipitated solid was collected and purified by reversed-phase column chromatography under usual conditions, obtaining 2.7 g of the title compound.
Determination of Antibacterial Activity
MICswere determined by microdilution methodology. With the exception of the study of VanA enterococci (Table 6 ), in which inocula were 5 x 105 CFU/ml, the inocula were 104 CFU/ml. Iso-Sensitest broth (Oxoid) was used for staphylococci and enterococci; Todd-Hewitt broth (Difco) was used for streptococci. Incubation was at 37°C for 24 hours. Amide IV (10.8 g) was also prepared from II (24g) according to Method c. The benzyl carbamate N15-CBZ-II was not isolated. See Method d, general procedure.
